secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0001193125-24-269398
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm pauses endometrial cancer program update; in talks with FDA about Phase 3 trial
--------------------------------------------------------------------------------

- Company in discussions with FDA regarding evolving treatment landscape for endometrial cancer and its impact on Phase 3 XPORT-EC-042 trial.
- Karyopharm will not discuss endometrial cancer program at Piper Sandler conference on Dec 3, 2024.
- Company intends to provide update on endometrial cancer program after FDA discussion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524269398/0001193125-24-269398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524269398/d916753d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-269398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer